Scott Kopetz, MD, on Colorectal Cancer: Results of the SWOG 1406 Trial

2017 Gastrointestinal Cancers Symposium
Tweet this page

Scott Kopetz, MD, of The University of Texas MD Anderson Cancer Center, discusses study findings on irinotecan and cetuximab with or without vemurafenib in BRAF-mutant metastatic colorectal cancer (Abstract 520).

Advertisement

Advertisement



;
Advertisement

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.